Jinbin Xu

Dr. Jinbin Xu

Washington University School of Medicine St. Louis, MO, USA
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Cell
Verified
Journal Article
Closed access
JGJohannes Gräff
Johannes Gräff
NJNadine F. Joseph
Nadine F. Joseph
MHMeryl E. Horn
Meryl E. Horn
ASAlireza Samiei
Alireza Samiei
JMJia Meng
Jia Meng
LTLi-Huei Tsai
Li-Huei Tsai

5 July 2011 in Nature Communications
Verified
Journal Article
Open access
PDF file
Jinbin XuJinbin Xu
Jinbin Xu
CZChenbo Zeng
Chenbo Zeng
WCWenhua Chu
Wenhua Chu
FPFenghui Pan
Fenghui Pan
JRJustin M. Rothfuss
Justin M. Rothfuss
Robert H. MachRobert H. Mach
Robert H. Mach
The sigma-2 receptor, whose gene remains to be cloned, has been validated as a biomarker for tumour cell proliferation. Here we report the use of a novel photoaffinity probe, WC-21 , to identify the sigma-2 receptor-binding site. WC-21 , a sigma-2 ligand containing both a photoactive azide moiety and a fluorescein isothiocyanate group, irreversibly labels sigma-2 receptors in rat liver; the membrane-bound protein was identified as PGRMC1 (progesterone receptor membrane component 1). Immunocytochemistry reveals that both PGRMC1 and SW120 , a fluorescent sigma-2 receptor ligand, colocalize with molecular markers of the endoplasmic reticulum and mitochondria in HeLa cells. Overexpression and knockdown of the PGRMC1 protein results in an increase and a decrease in binding of a sigma-2 selective radioligand, respectively. The identification of the putative sigma-2 receptor-binding site as PGRMC1 should stimulate the development of unique imaging agents and cancer therapeutics that target the sigma-2 receptor/PGRMC1 complex.

12 November 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NINicholas Izzo
Nicholas Izzo
Jinbin XuJinbin Xu
Jinbin Xu
CZChenbo Zeng
Chenbo Zeng
MKMolly J. Kirk
Molly J. Kirk
KMKelsie Mozzoni
Kelsie Mozzoni
SCSusan M. Catalano
Susan M. Catalano
Amyloid beta (Abeta) 1–42 oligomers accumulate in brains of patients with Mild Cognitive Impairment (MCI) and disrupt synaptic plasticity processes that underlie memory formation. Synaptic binding of Abeta oligomers to several putative receptor proteins is reported to inhibit long-term potentiation, affect membrane trafficking and induce reversible spine loss in neurons, leading to impaired cognitive performance and ultimately to anterograde amnesia in the early stages of Alzheimer's disease (AD). We have identified a receptor not previously associated with AD that mediates the binding of Abeta oligomers to neurons, and describe novel therapeutic antagonists of this receptor capable of blocking Abeta toxic effects on synapses in vitro and cognitive deficits in vivo. Knockdown of sigma-2/PGRMC1 (progesterone receptor membrane component 1) protein expression in vitro using siRNA results in a highly correlated reduction in binding of exogenous Abeta oligomers to neurons of more than 90%. Expression of sigma-2/PGRMC1 is upregulated in vitro by treatment with Abeta oligomers, and is dysregulated in Alzheimer's disease patients' brain compared to age-matched, normal individuals. Specific, high affinity small molecule receptor antagonists and antibodies raised against specific regions on this receptor can displace synthetic Abeta oligomer binding to synaptic puncta in vitro and displace endogenous human AD patient oligomers from brain tissue sections in a dose-dependent manner. These receptor antagonists prevent and reverse the effects of Abeta oligomers on membrane trafficking and synapse loss in vitro and cognitive deficits in AD mouse models. These findings suggest sigma-2/PGRMC1 receptors mediate saturable oligomer binding to synaptic puncta on neurons and that brain penetrant, small molecules can displace endogenous and synthetic oligomers and improve cognitive deficits in AD models. We propose that sigma-2/PGRMC1 is a key mediator of the pathological effects of Abeta oligomers in AD and is a tractable target for small molecule disease-modifying therapeutics.

6 February 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DBDevika P. Bagchi
Devika P. Bagchi
LYLihai Yu
Lihai Yu
JPJoel S. Perlmutter
Joel S. Perlmutter
Jinbin XuJinbin Xu
Jinbin Xu
Robert H. MachRobert H. Mach
Robert H. Mach
PKPaul T. Kotzbauer
Paul T. Kotzbauer
Accumulation of α-synuclein (α-syn) fibrils in Lewy bodies and Lewy neurites is the pathological hallmark of Parkinson disease (PD). Ligands that bind α-syn fibrils could be utilized as imaging agents to improve the diagnosis of PD and to monitor disease progression. However, ligands for α-syn fibrils in PD brain tissue have not been previously identified and the feasibility of quantifying α-syn fibrils in brain tissue is unknown. We report the identification of the 125I-labeled α-syn radioligand SIL23. [125I]SIL23 binds α-syn fibrils in postmortem brain tissue from PD patients as well as an α-syn transgenic mouse model for PD. The density of SIL23 binding sites correlates with the level of fibrillar α-syn in PD brain tissue, and [125I]SIL23 binding site densities in brain tissue are sufficiently high to enable in vivo imaging with high affinity ligands. These results identify a SIL23 binding site on α-syn fibrils that is a feasible target for development of an α-syn imaging agent. The affinity of SIL23 for α-syn and its selectivity for α-syn versus Aβ and tau fibrils is not optimal for imaging fibrillar α-syn in vivo, but we show that SIL23 competitive binding assays can be used to screen additional ligands for suitable affinity and selectivity, which will accelerate the development of an α-syn imaging agent for PD.

15 July 2007 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
HKHiroyuki Kashiwagi
Hiroyuki Kashiwagi
JMJonathan E McDunn
Jonathan E McDunn
PSPeter O Simon
Peter O Simon
PGPeter S Goedegebuure
Peter S Goedegebuure
Jinbin XuJinbin Xu
Jinbin Xu
WHWilliam G Hawkins
William G Hawkins
Background: Resistance to modern adjuvant treatment is in part due to the failure of programmed cell death. Therefore the molecules that execute the apoptotic program are potential targets for the development of anti-cancer therapeutics. The sigma-2 receptor has been found to be over-expressed in some types of malignant tumors, and, recently, small molecule ligands to the sigma-2 receptor were found to induce cancer cell apoptosis.Results: The sigma-2 receptor was expressed at high levels in both human and murine pancreas cancer cell lines, with minimal or limited expression in normal tissues, including: brain, kidney, liver, lung, pancreas and spleen. Micro-PET imaging was used to demonstrate that the sigma-2 receptor was preferentially expressed in tumor as opposed to normal tissues in pancreas tumor allograft-bearing mice. Two structurally distinct sigma-2 receptor ligands, SV119 and WC26, were found to induce apoptosis to mice and human pancreatic cancer cellsin vitroandin vivo. Sigma-2 receptor ligands induced apoptosis in a dose dependent fashion in all pancreatic cell lines tested. At the highest dose tested (10 μM), all sigma-2 receptor ligands induced 10–20% apoptosis in all pancreatic cancer cell lines tested (p < 0.05). In pancreas tumor allograft-bearing mice, a single bolus dose of WC26 caused approximately 50% apoptosis in the tumor compared to no appreciable apoptosis in tumor-bearing, vehicle-injected control animals (p < 0.0001). WC26 significantly slowed tumor growth after a 5 day treatment compared to vehicle-injected control animals (p < 0.0001) and blood chemistry panels suggested that there is minimal peripheral toxicity.Conclusion: We demonstrate a novel therapeutic strategy that induces a significant increase in pancreas cancer cell death. This strategy highlights a new potential target for the treatment of pancreas cancer, which has little in the way of effective treatments.

15 July 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
WCWenhua Chu
Wenhua Chu
DZDong Zhou
Dong Zhou
VGVrinda Gaba
Vrinda Gaba
JLJialu Liu
Jialu Liu
SLShihong Li
Shihong Li
Robert H. MachRobert H. Mach
Robert H. Mach